ImmuPharma appoints new adviser
January 24, 2017ImmuPharma has appointed Northland Capital Partners as its Nominated Adviser and sole broker with immediate effect.
ImmuPharma is a pharmaceutical development company listed since 2006 on AIM of the London Stock Exchange (LSE:IMM), focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need.
